Targeting HIF-1 for cancer therapy - A review of the evidence
Narrative review: HIF-1 drives tumor energy use, angiogenesis, invasion and survival. Evidence is mainly preclinical; clinical targeting remains uncertain.
Authors
- Antonio Conte (ORCID: https://orcid.org/0009-0001-3718-6780)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24340723
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00